SA Asks: Which oncology companies are attractive M&A targets?
Source: SeekingAlpha
2025-05-30 15:00:49 ET
More on Gilead Sciences, Bristol-Myers Squibb Company , etc.
- Bristol-Myers Squibb: This Undervalued Dog Needs An Option Collar
- Bristol-Myers: Among The Cheapest Pharma Names, Now Yielding Above 5%
- Bristol-Myers Squibb At ASCO 2025: A Resilient Play Amid Market Turbulence
- Global cancer drug sales growth to slow amid patent cliffs: report
- Autolus Therapeutics gets EU endorsement for leukemia treatment
Read the full article on Seeking Alpha
For further details see:
SA Asks: Which oncology companies are attractive M&A targets?
Autolus Therapeutics plc
NASDAQ: AUTL
AUTL Trading
22.54% G/L:
$1.93 Last:
4,124,476 Volume:
$1.62 Open:
AUTL Latest News
May 14, 2026 07:00:00 am
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business UpdatesMay 05, 2026 07:00:00 am
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026April 29, 2026 04:05:00 pm
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost ReductionAUTL Stock Data
$387,238,481
109,839,996
N/A
49
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
